Extensions of Resurgence as Choice (NCT05537610) | Clinical Trial Compass
RecruitingNot Applicable
Extensions of Resurgence as Choice
United States30 participantsStarted 2023-02-01
Plain-language summary
Although behavioral treatments for decreasing destructive behavior, such as differential reinforcement of alternative behavior (DRA), are effective in the clinic, problem behavior often returns when a caregiver does not give the child their way in the natural environment (e.g., caregiver is busy with an infant sibling). This form of treatment relapse is known as resurgence. The goal of the current study is to evaluate whether alternating sessions in which the child can have their way (i.e., "on" sessions) with sessions in which the child can not have their way (i.e., "off" sessions) helps to mitigate resurgence.
Who can participate
Age range3 Years – 17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. boys and girls from ages 3 to 17;
✓. problem behavior that occurs at least 10 times a day, despite previous treatment;
✓. problem behavior maintained by social positive reinforcement;
✓. stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment;
✓. on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free;
✓. stable educational plan and placement with no anticipated changes during the child's treatment.
Exclusion criteria
✕. patients who do not meet the inclusion criteria;
✕. patients currently receiving 15 or more hours per week of treatment for their problem behavior;
✕. DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism);
What they're measuring
1
Rate of problem behavior during resurgence test
Timeframe: 5 years
Trial details
NCT IDNCT05537610
SponsorRutgers, The State University of New Jersey
. a comorbid health condition or major mental disorder that would interfere with study participation;
✕. occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment;
✕. patients requiring changes to protective supports for self-injury or drug treatment, but we will invite these patients to participate when protective supports and drug regimen are stable.